Horizon begins phase four clinical trial of Genmab drug

Horizon Therapeutics enters phase four clinical trial of the drug Tepezza to learn more about its effects on patients with chronic Graves' ophthalmopathy. The company has reaped millions from the already FDA-approved drug.

Photo: Lars Møller / Genmab / PR

The drug Tepezza has already been celebrated by the pharmaceutical industry as the first FDA-approved drug for the treatment of thyroid eye disease, also known as Graves' ophthalmopathy. The company behind the drug, Horizon Therapeutics, is now eager to better understand the long-term use of the drug.

This is why Horizon is beginning a new clinical trial of the drug, which was originally developed by Danish biotech company Genmab, to study the effects of the drug on the chronic version of the disease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs